Nrx pharmaceuticals (nasdaq:nrxp) reports third quarter and year to date 2024 financial results and provides business update

On track to file new drug applications (ndas) for nrx-100 (iv ketamine) in treating suicidal ideation in depression, including bipolar depression and nrx-101 (oral d-cycloserine/lurasidone) for accelerated approval in bipolar depression with suicidality or akathisia by year end 2024 with 2025 pdufa date forecast. hope therapeutics acquiring interventional psychiatry clinics; key to developing a best-in-class network of care to prevent suicide, continues to expect first revenue by year-end 2024.
NRXP Ratings Summary
NRXP Quant Ranking